This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.
Issue link: http://cmesupplements.eyeworld.org/i/759858
EyeWorld September 2016 Supported by an unrestricted educational grant from Abbott Medical Optics Designation Statement The American Society of Cataract and Refractive Surgery designates this enduring materials educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. ™ Physi- cians should claim only credit commensurate with the extent of their participation in the activity. Claiming Credit To claim credit, participants must visit bit.ly/2gVjCDk to review content and down- load the post-activity test and credit claim. All participants must pass the post-activity test with a score of 75% or higher to earn credit. Alternatively, the post-test form included in this supplement may be faxed to the number indicated for credit to be awarded, and a certificate will be mailed within 2 weeks. When viewing online or downloading the ma- terial, standard internet access is required. Adobe Acrobat Reader is needed to view the materials. CME credit is valid through June 30, 2017. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at firstname.lastname@example.org or 703-591-2220. Financial Interest Disclosures John Berdahl, MD, has earned a royalty or derived other financial gain from Imprimis and Ocular Surgical Data. He has an investment interest in DigiSight, Omega Ophthalmics, and Vision 5. Dr. Berdahl has received a retainer, ad hoc fees or other con- sulting income from: Abbott Medical Optics, Alcon Laboratories, Avedro, Bausch + Lomb, Calhoun Vision, ClarVista, DigiSight, Enviseo, Glaukos, Imprimis, Ocular Therapeutix, Omega Ophthalmics, Ocular Surgical Data, Vision 5, and Vittamed. He is a member of the speakers bureaus of Glaukos and Ocular Therapeutix. Rosa Braga-Mele, MD, FRCSC, is a member of the speakers bureaus of Alcon Laborato- ries and Allergan. Daniel Chang, MD, has an investment inter- est in Omega Ophthalmics. He has received a retainer, ad hoc fees, or other consulting income from: Abbott Medical Optics, Allergan, Carl Zeiss Meditec, Mynosys Cellular Devices, and Omega Ophthalmics. Dr. Chang has received expense reimbursement from and is a member of the speakers bureaus of Abbott Medical Optics and Carl Zeiss Meditec. He has received research funding from Abbott Medical Optics and Mynosys Cellular Devices. Daniel Durrie, MD, has an investment inter- est in, has received expense reimbursement from, and has received a retainer, ad hoc fees or other consulting income from AcuFocus, Alphaeon, and Strathspey Crown. He has received research funding from AcuFocus, Alcon, Allergan, Avedro, and EyeGate Pharma. Dr. Durrie has received expense reimburse- ment from Avedro and Hoopes Durrie Rivera Research. Staff members: Kristen Covington and Laura Johnson have no ophthalmic-related financial interests. 365 Curriculum Presbyopia Presbyopia correction: Exploring surgical options, expectations, and postoperative error continued on page 2 by Daniel Durrie, MD Describing the stages of presbyopia: Understanding its onset and progression DLS stages Patients usually enter stage 1 of DLS at an average age of 43. In stage 1, the lens is clear and colorless, but the lens los- es the ability to change power. As a result, most patients have When we explain this to our patients, they understand it well. Previously, patients knew their eyes changed during middle age and that cataracts may develop later, but no one explained how the lens was changing. New terminology gains momentum in ophthalmic practices A new three-stage classification system is helping cataract surgeons communicate with their colleagues and patients about the normal phases of crystalline lens change that occur with aging. When we review the stages of dysfunc- tional lens syndrome (DLS), we not only describe the way the lens changes but can correlate these changes with treatments that are most ap- propriate at each stage. 1,2 Illustrative analogy During human embryon- ic development, a piece of ectodermal tissue splits off to become the crystalline lens. Consequently, it ages simi- larly to the skin. As disulfide bonds accumulate inside the lens through all three stages, the lens loses flexibility and density increases. " With new diagnostic tools, we can show patients the color, appearance, and density of the lens and how they affect vision. " –Daniel Durrie, MD Accreditation Statement This activity has been planned and imple- mented in accordance with the accreditation requirements and policies of the Accredi- tation Council for Continuing Medical Edu- cation through the joint providership of the American Society of Cataract and Refractive Surgery (ASCRS) and EyeWorld. ASCRS is ac- credited by the ACCME to provide continuing medical education for physicians. Educational Objectives Ophthalmologists who participate in this activity will: • Accurately describe the progressive diagnosis of presbyopia and the optical fundamentals of correction options, uti- lizing the appropriate current terminology of presbyopia to describe all stages of the disease state • Compare and contrast presbyopia treatment options to match solutions to patients' needs, and describe range of vision functions as related to patients' needs • Implement a lower threshold for accept- able pseudophakic refractive error levels in presbyopia-corrected patients, and identify steps to mitigate refractive sur- prises and other key variables to increase postoperative success EyeWorld January 2017